STAA Staar Surgical Co.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel. Both will serve on the Company’s executive committee and report to Tom Frinzi, STAAR Surgical’s President and CEO.

This press release features multimedia. View the full release here:

Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business Wire)

Nancy Sabin, Chief Marketing Officer, STAAR Surgical (Photo: Business Wire)

“We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience. They will play an integral role in accelerating our momentum and thereby growing the market for our surgeon customers who provide patients visual freedom from contact lenses and glasses with our lens-based technology,” said Tom Frinzi, President and CEO of STAAR Surgical. “Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally. She is a proven commercial leader with an extensive track record of delivering growth within consumer products, OTC pharmaceuticals and medical devices during her 20-year career with various franchises at Johnson & Johnson. Nate takes on an important role as our new General Counsel overseeing our legal functions globally. Nate brings to STAAR extensive experience providing legal advice and counsel to public companies, including 15 years in med-tech. He joins us from NuVasive where he was instrumental in its successful $3 billion merger with Globus Medical.”

Frinzi continued, “I would like to express my utmost gratitude to Sam Gesten, STAAR’s former general counsel, who retired after 12 years of service earlier this year. We are grateful for his tireless work in moving the company forward and wish him all the very best in the future.”

Nancy Sabin joined the team from Johnson & Johnson (J&J) where she most recently served as VP of Marketing and Connected Commerce for J&J Vision managing based marketing, digital strategy and connected commerce functions for the ACUVUE™ contact lens business in the U.S., one of J&J’s businesses with annual sales of at least $1 billion. Prior, she led Global Marketing for J&J Vision on the surgical side, driving innovation and equity for its industry leading global intraocular lenses. She has also held marketing leadership roles across J&J Consumer and J&J MedTech; with responsibility for driving growth and building global brands like TYLENOL™; ZYRTEC™ and ETHICON™. Nancy holds an M.B.A. from the University of Pennsylvania’s Wharton School of Business and a B.S. in Engineering from Duke University.

Ms. Sabin stated, “I am delighted to be a part of STAAR during this critical phase in the company's growth. I am a huge believer in the transformation made possible thanks to our EVO ICLs and look forward to elevating the STAAR and EVO brands among surgeons and their patients. I am excited and honored to lead our marketing teams worldwide.”

Nathaniel Sisitsky joined STAAR Surgical from NuVasive, Inc., a medical device company, where he served as Senior Vice President, General Counsel and Corporate Secretary since 2018. Prior to joining NuVasive, he served as Vice President and Associate General Counsel at CareFusion Corporation, a global medical technology company, and as Vice President, Legal – Corporate Finance at American Tower Corporation, a global owner and operator of wireless communication sites. Prior to joining American Tower, Nate was a Junior Partner in the Corporate Department of Wilmer Cutler Pickering Hale and Dorr (WilmerHale). He holds a J.D. from New York University School of Law and a B.A. in Political Science and Economics from Emory University.

“I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at .

EN
01/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Staar Surgical Co.

Staar Surgical Co: 1 director

A director at Staar Surgical Co bought 1,315 shares at 37.990USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

 PRESS RELEASE

STAAR Surgical Reports Second Quarter 2024 Results

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the second quarter ended June 28, 2024. Second Quarter 2024 Overview Net sales up 7% to $99.0 million and up 9% to $100.4 million in constant currency ICL sales up 7% to $99.4 million and units up 3% Gross margin at 79.2% vs. 76.6% year ago Net income of $7.4 million or $0.15 per share vs. net income of $6.1 million or $0...

 PRESS RELEASE

STAAR Surgical to Report Second Quarter Results on August 7, 2024

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the second quarter ended June 28, 2024, on Wednesday, August 7, 2024, after the market close. Event: STAAR Surgical 2Q 2024 Financial Results Webcast Date: Wednesday, August 7, 2024 Time: 4:15 p.m. ET / 1:15 p.m. PT Location: STAAR will also host an earnings webcast on Wednesday, August 7 at 4:15 p.m. Eastern...

 PRESS RELEASE

STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth ...

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Canaccord Genuity 44th Annual Growth Conference, which will be held in Boston, Massachusetts. Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Tuesday, August 13, 2024, at 8:30 a.m. Eastern T...

 PRESS RELEASE

STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Heal...

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida. Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Wednesday, June 12, 2024, at 8:00 a.m. Eastern T...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch